Sequenom Reports 20 Percent Increase in Q1 Revenues | GenomeWeb

NEW YORK (GenomeWeb) – Sequenom reported after the close of the market Thursday that its first quarter revenues climbed 20 percent compared to the first quarter of 2013, driven by its diagnostics business, including sales of its MaterniT21 Plus noninvasive prenatal test for fetal aneuploidy.

The San Diego-based molecular diagnostics firm reported total Q1 revenues of $46.3 million, compared to $38.5 million in the first quarter 2013. Revenues were slightly above the Wall Street consensus estimate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.